Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
16 studies found for:    AMG145 | Phase 3
Show Display Options
Rank Status Study
1 Completed Study of LDL-Cholesterol Reduction Using Evolocumab (AMG145) in Japanese Patients With Advanced Cardiovascular Risk
Condition: Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events
Interventions: Drug: Statin;   Other: Placebo;   Biological: Study Drug
2 Completed Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities
Condition: Homozygous Familial Hypercholesterolemia
Interventions: Biological: Evolocumab (AMG145);   Other: Placebo
3 Recruiting Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody
Condition: Primary Hyperlipidemia and Mixed Dyslipidemia
Interventions: Biological: Evolocumab (AMG 145);   Drug: Atorvastatin;   Drug: Placebo
4 Completed A Randomized, Multi-center Clinical Study in Subjects With Hypercholesterolemia or Mixed Dyslipidemia
Conditions: Primary Hypercholesterolemia;   Mixed Dyslipidemia
Intervention: Biological: evolocumab (AMG 145)
5 Completed A Multi-center, Randomized Study in Subjects With Primary Hypercholesterolemia or Mixed Dyslipidemia
Conditions: Primary Hypercholesterolemia;   Mixed Dyslipidemia
Intervention: Biological: evolocumab (AMG 145)
6 Recruiting Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders
Condition: Severe Familial Hypercholesterolemia
Intervention: Biological: Evolocumab (AMG145)
7 Recruiting GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound
Condition: Hypercholesterolemia
Interventions: Biological: Evolocumab (AMG 145);   Other: Placebo
8 Completed Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study
Condition: Hypercholesterolemia
Interventions: Biological: Evolocumab (AMG 145) + background lipid lowering therapy;   Biological: Placebo + background lipid lowering therapy;   Drug: Atorvastatin 10 mg;   Drug: Atorvastatin 80 mg;   Drug: Atorvastatin 80 mg + Ezetimibe 10 mg;   Other: Diet Only (no drug)
9 Completed LDL-C Assessment w/ PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2
Condition: Hyperlipidemia
Interventions: Biological: evolocumab (AMG 145);   Other: Ezetimibe;   Other: Placebo (administered subcutaneously);   Other: Placebo (administered orally);   Drug: Atorvastatin;   Drug: Rosuvastatin;   Drug: Simvastatin
10 Completed Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2
Condition: Hyperlipidemia
Interventions: Biological: Evolocumab (AMG 145);   Other: Placebo
11 Completed Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2
Condition: Hyperlipidemia
Interventions: Biological: Evolocumab (AMG 145);   Other: Placebo (administered subcutaneously);   Drug: Ezetimibe;   Other: Placebo (administered orally)
12 Completed Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2
Condition: Hyperlipidemia
Interventions: Biological: Evolocumab (AMG 145);   Drug: Ezetimibe;   Other: Placebo (administered subcutaneously);   Other: Placebo (administered orally)
13 Recruiting Open Label Study of Long Term Evaluation Against LDL-C Trial-2
Condition: Hyperlipidemia and Mixed Dyslipidemia
Interventions: Biological: evolocumab (AMG 145) and standard of care;   Other: Standard of care
14 Recruiting Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3
Condition: Hyperlipidemia
Interventions: Drug: Part A, Atorvastatin;   Other: Part A, Placebo (administered orally);   Drug: Part B, Evolocumab;   Other: Part B, Placebo (administered orally);   Drug: Part B, Ezetimibe;   Other: Part B, Placebo (administered subcutaneously);   Drug: Part C, Evolocumab
15 Recruiting Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Condition: Dyslipidemia
Interventions: Biological: Evolocumab (AMG 145);   Other: Placebo;   Drug: Effective statin therapy
16 Recruiting Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects
Condition: Dyslipidemia
Interventions: Biological: Evolocumab (AMG 145);   Other: Placebo;   Drug: Effective statin therapy

Indicates status has not been verified in more than two years